International Variation in Severe Exacerbation Rates in Patients With Severe Asthma

Tae Yoon Lee,David Price,Chandra Prakash Yadav,Rupsa Roy,Laura Huey Mien Lim,Eileen Wang,Michael E Wechsler,David J Jackson,John Busby,Liam G Heaney,Paul E Pfeffer,Bassam Mahboub,Diahn-Warng Perng Steve,Borja G Cosio,Luis Perez-de-Llano,Riyad Al-Lehebi,Désirée Larenas-Linnemann,Mona Al-Ahmad,Chin Kook Rhee,Takashi Iwanaga,Enrico Heffler,Giorgio Walter Canonica,Richard Costello,Nikolaos G Papadopoulos,Andriana I Papaioannou,Celeste M Porsbjerg,Carlos A Torres-Duque,George C Christoff,Todor A Popov,Mark Hew,Matthew Peters,Peter G Gibson,Jorge Maspero,Celine Bergeron,Saraid Cerda,Elvia Angelica Contreras-Contreras,Wenjia Chen,Mohsen Sadatsafavi

DOI: https://doi.org/10.1016/j.chest.2024.02.029

IF: 9.6

Chest

Abstract:Background: Exacerbation frequency strongly influences treatment choices in patients with severe asthma. Research question: What is the extent of the variability of exacerbation rate across countries and its implications in disease management? Study design and methods: We retrieved data from the International Severe Asthma Registry, an international observational cohort of patients with a clinical diagnosis of severe asthma. We identified patients aged ≥ 18 years who did not initiate any biologics prior to baseline visit. A severe exacerbation was defined as the use of oral corticosteroids for ≥ 3 days or asthma-related hospitalization/ED visit. A series of negative binomial models were applied to estimate country-specific severe exacerbation rates during 365 days of follow-up, starting from a naive model with country as the only variable to an adjusted model with country as a random-effect term and patient and disease characteristics as independent variables. Results: The final sample included 7,510 patients from 17 countries (56% from the United States), contributing to 1,939 severe exacerbations (0.27/person-year). There was large between-country variation in observed severe exacerbation rate (minimum, 0.04 [Argentina]; maximum, 0.88 [Saudi Arabia]; interquartile range, 0.13-0.54), which remained substantial after adjusting for patient characteristics and sampling variability (interquartile range, 0.16-0.39). Interpretation: Individuals with similar patient characteristics but coming from different jurisdictions have varied severe exacerbation risks, even after controlling for patient and disease characteristics. This suggests unknown patient factors or system-level variations at play. Disease management guidelines should recognize such between-country variability. Risk prediction models that are calibrated for each jurisdiction will be needed to optimize treatment strategies.